The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended authorization for five new drugs, including Madrigal Pharmaceuticals’ resmetirom (Rezdiffra), a first-in-Europe therapy for noncirrhotic metabolic dysfunction-associated steatohepatitis (NASH). Other approvals include treatments for desmoid tumors and chronic inflammatory demyelinating polyneuropathy. Eli Lilly’s Alzheimer’s drug Kisunla remains under re-examination following prior rejections, highlighting ongoing regulatory scrutiny within neurodegenerative disease treatments.